Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Division of Nephrology and Hypertension, Osaka City General Hospital, Osaka, Japan.
J Pharmacol Sci. 2018 Jun;137(2):220-223. doi: 10.1016/j.jphs.2017.10.006. Epub 2017 Oct 28.
We aimed to examine the effects of a sodium glucose co-transporter 2 (SGLT2) inhibitor on systemic and intrarenal renin-angiotensin system (RAS) in subtotally nephrectomized non-diabetic rats, a model of chronic kidney disease (CKD). Oral administration of the selective SGLT2 inhibitor, TA-1887 (10 mg/kg/day), for 10 weeks induced glycosuria. However, plasma renin activity, plasma angiotensinogen levels, kidney angiotensin II contents and renal injury were not significantly affected by TA-1887. These data indicate that chronic treatment with an SGLT2 inhibitor does not activate the systemic and intrarenal RAS in subjects with non-diabetic CKD.
我们旨在研究钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂对部分肾切除非糖尿病大鼠（一种慢性肾脏病模型）全身和肾内肾素-血管紧张素系统（RAS）的影响。选择性 SGLT2 抑制剂 TA-1887（10mg/kg/天）口服给药 10 周可诱导糖尿。然而，TA-1887 对血浆肾素活性、血浆血管紧张素原水平、肾脏血管紧张素 II 含量和肾脏损伤没有显著影响。这些数据表明，在非糖尿病 CKD 患者中，慢性 SGLT2 抑制剂治疗不会激活全身和肾内 RAS。
